Recording: PARP Inhibitor in Prostate Cancer. Part 3
This recording will focus on how the availability of novel systemic therapies (such as PARP inhibitors) will revolutionise the management of advanced prostate cancer patients.
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | Not approved |
| Duration | Approx. 60 minutes |
The role of precision medicine in different settings in the management of men affected by prostate cancer will be discussed. A practical guide will be provided for urologists, radiation oncologists and medical oncologists who will prescribe PARP inhibitors in prostate cancer patients. The potential role of treatment combination with PARP inhibitors and ongoing prospective trials in this setting will be analysed also.
The UROwebinar will take approximately one hour and includes the possibility to ask questions during the Q&A.
Please find the links for Part I and Part 2 that were held earlier in the year.